Nebilan (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebilan, is a beta‑blocker presented as an oral tablet for oral use. It selectively blocks β1‑adrenergic receptors and promotes nitric‑oxide mediated vasodilation, helping to lower blood pressure and improve vascular health in adult patients.

GNH USA supplies Nebilan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets.

Nebivolol is a selective β1‑adrenergic blocker used primarily in the management of hypertension and related cardiovascular conditions. - Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and heart attack. - Heart failure with reduced ejection fraction: improves cardiac output and may decrease hospitalization rates. - Cardiovascular risk reduction in hypertensive patients: helps prevent major adverse cardiovascular events when combined with standard therapy.

Nebivolol may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Dizziness or light‑headedness: especially after standing. - Fatigue: feeling of tiredness or reduced energy. - Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate that may require medical attention. - Severe hypotension: marked drop in blood pressure leading to fainting. - Acute bronchospasm: sudden narrowing of airways, particularly in patients with asthma.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular assessment: evaluate heart rate and blood pressure before initiation. - Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchoconstriction. - Diabetes mellitus: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms. - Liver impairment: dose adjustment may be required in moderate to severe hepatic dysfunction. - Concomitant AV nodal blockers: avoid excessive bradycardia when combined with other rate‑controlling agents. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined use with non‑selective β‑blockers: may cause excessive β‑blockade and bradycardia. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma levels, raising risk of adverse effects. - Calcium channel blockers (verapamil, diltiazem): can enhance negative inotropic and chronotropic effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (ACE inhibitors, diuretics): may produce additive blood pressure lowering. - Antidiabetic drugs (insulin, sulfonylureas): β‑blockade may mask hypoglycaemia signs. - Antidepressants (tricyclics): may increase risk of cardiac conduction abnormalities.